Urologic Oncology Articles

10-Year PROTECT Data Underscore Significance of Precision Medicine in Prostate Cancer
Malcolm Mason, MD, discusses the significance of the 10-year follow-up of the PROTECT study for patients with prostate cancer and what it means for the field going forward.
CTCs Better Overall Survival Predictors Than PSA in mCRPC
An analysis of results from 5 clinical trials showed that circulating tumor cell (CTC) conversion and CTC value ≥ 1 at baseline were superior predictors of overall survival than PSA in men with metastatic castration-resistant prostate cancer.
Genetic Model Predicts Age of Onset for Aggressive Prostate Cancer
By combining data from genome-wide association studies with epidemiological surveys, investigators say they have developed a genetic tool that can predict age of onset for aggressive prostate cancer.
Published Data Demonstrate Avelumab Activity in Platinum-Refractory Bladder Cancer
The PD-L1 inhibitor avelumab induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.
Abiraterone Associated With Improved PROs in Metastatic Prostate Cancer
Men with newly diagnosed mCRPC in the global LATITUDE trial reported clinical improvements in pain progression, prostate cancer symptoms, fatigue, functional decline, and overallHR-QOL following treatment with abiraterone acetate plus prednisone.
Molecular Subtypes Correlate With Outcomes in RCC
Molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with significant differences seen in overall survival and disease-free survival between groupings.
Layering of therapies and advances in next-generation imaging and sequencing are key reasons that outcomes are improving in advanced prostate cancer.
For patients with oligorecurrent prostate cancer, androgen deprivation therapy–free survival was superior for those assigned to metastasis-directed therapy versus surveillance.
Bipolar Androgen Therapy Effective After Enzalutamide in mCRPC
One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.
Combinations Continue to Advance RCC Treatment
Rana R. McKay, MD, discusses the evolving management of patients with advanced RCC, specifically the future of combinations of with immunotherapy regimens.
Publication Bottom Border
Border Publication